There are currently 1011 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241
Recruiting
This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Gender:
All
Ages:
22 years and below
Trial Updated:
04/18/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Register for Updates
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05457556
Recruiting
This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical [haplo]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells... Read More
Gender:
All
Ages:
Between 6 months and 21 years
Trial Updated:
04/18/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia
Register for Updates
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318
Recruiting
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
04/18/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Register for Updates
Dissemination and Implementation of the Bright Bodies Intervention for Childhood Obesity
NCT05595161
Recruiting
This study will evaluate the effectiveness of the Bright Bodies intervention in improving body mass index (BMI) among 7-13 year-old children with obesity simultaneously with the impact of the implementation strategy on adoption, reach, fidelity, cost, and maintenance of the intervention in three heterogenous settings serving patients disproportionately affected by obesity.
Gender:
All
Ages:
Between 7 years and 13 years
Trial Updated:
04/18/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Obesity, Childhood
Register for Updates
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer
NCT05228275
Recruiting
This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the body's natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and numb... Read More
Gender:
All
Ages:
Between 6 months and 37 years
Trial Updated:
04/18/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: COVID-19 Infection, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Register for Updates
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
NCT03626688
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Register for Updates
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
NCT01656603
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
Gender:
All
Ages:
All
Trial Updated:
04/17/2024
Locations: Children's of Alabama, Birmingham, Alabama
Conditions: Infusion Reactions
Register for Updates
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
NCT04320342
Recruiting
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/17/2024
Locations: Chiesi Clinical Trial Site 840350, Birmingham, Alabama
Conditions: COPD, COPD Exacerbation
Register for Updates
Assessment of CCM in HF With Higher Ejection Fraction
NCT05064709
Recruiting
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: Grandview Medical Group Research, LLC, Birmingham, Alabama +1 locations
Conditions: Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Register for Updates
Study of Tecovirimat for Human Monkeypox Virus
NCT05534984
Recruiting
A5418 is a randomized, placebo-controlled, double-blind study to establish the efficacy of tecovirimat for the treatment of people with laboratory-confirmed or presumptive HMPXV disease.
Gender:
All
Ages:
All
Trial Updated:
04/16/2024
Locations: Alabama CRS, Birmingham, Alabama
Conditions: Monkeypox, MPOX
Register for Updates
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
NCT05879367
Recruiting
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
Register for Updates
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
NCT05001737
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Gender:
All
Ages:
Between 6 months and 80 years
Trial Updated:
04/16/2024
Locations: UAB Hospital, Birmingham, Alabama
Conditions: Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS
Register for Updates